Safety and tolerability of omalizumab

Summary Background Omalizumab (Xolair®) is a recombinant humanized monoclonal anti‐IgE antibody with proven efficacy in patients with moderate‐to‐severe and severe persistent allergic (IgE‐mediated) asthma. Objective To review clinical study data to assess the safety profile of omalizumab. Methods W...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical and experimental allergy 2009-06, Vol.39 (6), p.788-797
Hauptverfasser:	Corren, J., Casale, T. B., Lanier, B., Buhl, R., Holgate, S., Jimenez, P.
Format:	Artikel
Sprache:	eng
Schlagworte:	Anaphylaxis - immunology Anti-Asthmatic Agents - adverse effects Anti-Asthmatic Agents - therapeutic use anti-IgE Antibodies, Anti-Idiotypic - adverse effects Antibodies, Anti-Idiotypic - therapeutic use Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Humanized Asthma - drug therapy Biological and medical sciences Churg-Strauss Syndrome - immunology Clinical Trials as Topic Fundamental and applied biological sciences. Psychology Fundamental immunology Humans Infection - immunology Neoplasms - immunology Omalizumab safety Thrombocytopenia - immunology tolerability
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!